Morgan Stanley: DEA Likely To Reclassify GW Pharma’s Cannabinoid Therapy For US Launch

Morgan Stanley: DEA Likely To Reclassify GW Pharma's Cannabinoid Therapy For US LaunchMorgan Stanley expects the DEA to drop Epidiolex from Schedule I — the same level as cocaine, heroin and other illegal substances — to Schedule IV, where Xanax, Ambien and Tramadol rank. At worst, it would fall to Schedule III alongside moderately to lowly addictive drugs like codeine and anabolic steroids, Lebowitz said.



Yahoo Finance

You may also like...